LetibotulinumtoxinA: Complete Response Letter
A complete response letter is FDA's decision not to approve an application as submitted. See BLA 761225's history or Hugel, Inc.'s company page.
On Apr 12, 2023, FDA declined to approve LetibotulinumtoxinA (BLA 761225) from Hugel, Inc in its present form, citing facility inspections, product quality, microbiology. The application was later approved.
- Letter date: Apr 12, 2023
- Application: BLA 761225
- Since then: Approved
What FDA Cited
FDA's own section headings in the letter; each finds other letters citing itThe Letter
Text from openFDA(1) During a recent inspection of the Hugel, Inc. (FEI 3012163998) manufacturing and testing facility of drug substance and drug product for this application, our field investigator conveyed deficiencies to the representative of the facility. Satisfactory reso...… openFDA did not return the full text just now. Open it in the letter search.
Other Letters on This Application
- LetibotulinumtoxinAMar 31, 2022 · BLA 761225 · later approved
Record
- Company
- Hugel, Inc
- Application
- BLA 761225
- Status in openFDA
- Approved
- Review division
- Center for Drug Evaluation and Research
FDA has published complete response letters since 2025, with some redactions. The status is openFDA's: whether the application was eventually approved. openFDA complete response letters